White F J, Wang R Y
J Neurosci. 1986 Jan;6(1):274-80. doi: 10.1523/JNEUROSCI.06-01-00274.1986.
Extracellular single-unit recording and microiontophoretic techniques were used to characterize the pharmacological properties of dopamine (DA) receptors within the rat nucleus accumbens (NAc), a forebrain structure that receives a dense innervation from mesolimbic DA-containing neurons (A10 DA neurons) located in the ventral tegmental area (VTA). Of the NAc neurons tested, 75% were inhibited by microiontophoretic administration of the selective D-2 receptor agonist, LY-141865, whereas 38% were inhibited by microiontophoretic administration of the selective D-1 receptor agonist, SKF-38393. Of the 30 NAc neurons that were tested with both of these agonists, nine were inhibited by both agonists, 11 were inhibited only by LY-141865, five were inhibited only by SKF-38393, and five were not affected by either of these compounds. The inhibitory effects of LY-141865 were blocked and reversed by either intravenous or iontophoretic administration of the selective D-2 antagonist (-)-sulpiride, which, however, failed to alter the inhibitory effects of SKF-38393. In contrast, the purportedly selective D-1 antagonist, SCH-23390, selectively blocked and reversed the inhibitory effects of SKF-38393, suggesting that the two agonists were producing their inhibitory effects via distinct DA receptors. Additional experiments indicated that intravenous administration of LY-141865 caused a biphasic increase/decrease in the activity of NAc neurons. The initial rate increase was apparently due to disinhibition since it was also shown that D-2 DA receptors located on A10 DA neurons exhibited a 3-10-fold greater sensitivity to LY-141865 and DA as compared to the NAc D-2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
采用细胞外单单位记录和微量离子电泳技术,对大鼠伏隔核(NAc)内多巴胺(DA)受体的药理学特性进行了表征。伏隔核是一种前脑结构,接受来自腹侧被盖区(VTA)中含中脑边缘DA神经元(A10 DA神经元)的密集神经支配。在所测试的伏隔核神经元中,75%被微量离子电泳给予的选择性D-2受体激动剂LY-141865抑制,而38%被微量离子电泳给予的选择性D-1受体激动剂SKF-38393抑制。在同时用这两种激动剂测试的30个伏隔核神经元中,9个被两种激动剂均抑制,11个仅被LY-141865抑制,5个仅被SKF-38393抑制,5个不受这两种化合物中任何一种的影响。LY-141865的抑制作用可被静脉注射或离子电泳给予的选择性D-2拮抗剂(-)-舒必利阻断和逆转,然而,舒必利未能改变SKF-38393的抑制作用。相反,据称的选择性D-1拮抗剂SCH-23390选择性地阻断和逆转了SKF-38393的抑制作用,表明这两种激动剂通过不同的DA受体产生其抑制作用。额外的实验表明,静脉注射LY-141865会导致伏隔核神经元活动出现双相增加/减少。最初的速率增加显然是由于去抑制,因为还表明,与伏隔核D-2受体相比,位于A10 DA神经元上的D-2 DA受体对LY-141865和DA的敏感性高3至10倍。(摘要截短于250字)